DSM signs biologics manufacturing agreement with Recepta Biopharma

Covers the process development and cGMP manufacture of antibody at Netherlands plant

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has signed a biologics contract manufacturing agreement with its first Brazilian client, Recepta Biopharma in São Paulo.

The contract covers the process development and cGMP manufacture by DSM of one of Recepta's leading antibodies at its plant in Groningen, The Netherlands. Financial terms were not disclosed.

DSM started production to supply drug substance materials to be used in the initial clinical trials of this antibody in May.

Recepta Biopharma is a biotechnology company dedicated to the research and development of monoclonal antibodies to be used in the treatment of cancer.

Alexander Wessels, ceo of DSM Pharmaceutical Products said: ‘Working with Recepta in Brazil marks further advancement of DSM's stated strategy to grow its presence in high growth economies such as Brazil and South America.’

José Fernando Perez, ceo of Recepta Biopharma, added: ‘This manufacturing agreement with DSM moves us one step closer to serving patient needs for this important medical treatment. We are delighted to strengthen our global network of innovation to bring our new monoclonal antibodies to the market.’

Companies